DRL 16536

Drug Profile

DRL 16536

Alternative Names: DRF 16536

Latest Information Update: 26 May 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dr Reddys Laboratories
  • Developer Dr Reddys Laboratories; Perlecan Pharma
  • Class Antihyperglycaemics
  • Mechanism of Action Protein kinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetes mellitus

Most Recent Events

  • 26 May 2009 Discontinued - Phase-I for Diabetes mellitus in India (unspecified route)
  • 03 Oct 2005 Preclinical trials in Lipid metabolism disorders in India (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top